Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study

Marzano, A V;Genovese, G;Casazza, G;Moltrasio, C;Dapavo, P;Micali, G;Sirna, R;Gisondi, P;Patrizi, A;Dini, V;Bianchini, D;Bianchi, L;Fania, L;Prignano, F;Offidani, A;Atzori, L

Co-primo

Membro del Collaboration Group

;Bettoli, V;Cannavò, S P;Venturini, M;Bongiorno, M R;Costanzo, A;Fabbrocini, G;Peris, K

2021-01-01

---

Abstract

The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.